Literature DB >> 30675627

Bisphosphonate-induced orbital inflammation: more common than once thought?

L K Chehade1,2, D Curragh3, D Selva3.   

Abstract

To report two cases of bisphosphonate-induced orbital inflammation, discuss the clinic-radiological features and management options, and highlight the increasing frequency of an association previously considered extremely rare. A retrospective review of two cases presenting to our department, and review of the literature reporting this association. Two new cases of bisphosphonate-induced orbital inflammation were added to the literature. The first occurred in the context of a risedronate re-challenge, and the second with zoledronic acid. Both cases were managed successfully with topical steroids. Clinicians prescribing bisphosphonates, particularly for the first time, should be aware of the increasingly reported association with orbital inflammation. The presence of suggestive clinical features should prompt urgent referral to an ophthalmologist for appropriate management.

Entities:  

Keywords:  Bisphosphonate; Orbital inflammation; Risedronate; Zoledronic acid

Year:  2019        PMID: 30675627     DOI: 10.1007/s00198-019-04850-w

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  3 in total

1.  Risk of Cataract Surgery and Age-Related Macular Degeneration After Initiation of Denosumab vs Zoledronic Acid for Osteoporosis: A Multi-Database Cohort Study.

Authors:  Hemin Lee; Yinzhu Jin; Miin Roh; Theodore N Tsacogianis; Sangshin Park; Nam-Kyong Choi; Seoyoung C Kim
Journal:  Drugs Aging       Date:  2020-04       Impact factor: 3.923

Review 2.  Orbital Inflammation Caused by Aminobisphosphonates.

Authors:  J Gonzalez Barlatay; C Pagano Boza; G V Hernandez Gauna; J E Premoli
Journal:  J Ophthalmic Vis Res       Date:  2022-01-21

Review 3.  Bisphosphonate therapy in CKD: the current state of affairs.

Authors:  Matthew J Damasiewicz; Thomas L Nickolas
Journal:  Curr Opin Nephrol Hypertens       Date:  2020-03       Impact factor: 3.416

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.